Search for: "Anda Inc." Results 61 - 80 of 960
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Aug 2022, 11:39 am by Eileen McDermott
’s abbreviated new drug application (ANDA) does not infringe two patents owned by Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC (collectively, Par). [read post]
7 Apr 2014, 9:59 pm by Patent Docs
The case involved patentee Senju Pharmaceutical's (joined by Kyorin Pharmaceutical Co. and Allergan, Inc.) suit against Apotex in response to a Paragraph IV certification against Senju's patented ocular antimicrobial agent containing the drug Gatifloxacin as claimed in U.S. [read post]
16 May 2016, 9:59 pm by Patent Docs
Watson Laboratories, Inc., ANDA litigation over claim 4 of U.S. [read post]
11 Sep 2008, 4:55 am
Forest Laboratories, Inc. and Merck & Co. v. [read post]
14 Dec 2006, 6:47 am
Cir. 2006, 05-1313)   Impax had originally filed an ANDA with the FDA seeking approval to market generic riluzole (6-trifluoromethoxy-2-benzothiazolamine)  tablets for the treatment of ALS and prompting a suit for a declaratory judgment that Impax did not infringe, induce [...] [read post]
12 Dec 2011, 9:59 pm by Patent Docs
Mylan Pharmaceuticals Inc., an ANDA case brought before Judge Martini in the New Jersey District Court. [read post]
13 Aug 2020, 9:59 pm by Patent Docs
The case arose in ANDA litigation over IBSA's Tirosint® product, which is a soft gel capsule formulation of the active ingredient levothyroxine sodium, as claimed in U.S. [read post]
12 Aug 2010, 9:57 pm by Patent Docs
By Andrew Williams -- Last week, in King Pharmaceuticals, Inc. v. [read post]
28 Aug 2014, 9:29 pm by Patent Docs
Watson Laboratories, Inc., the Federal Circuit affirmed a finding by the District Court that a generic company could moot ANDA litigation by amending its application to exclude practice of an infringing article. [read post]
1 Sep 2014, 9:26 pm by Patent Docs
Watson Laboratories, Inc., the Federal Circuit affirmed a finding by the District Court that the generic ANDA challenger had not shown the asserted claims of the patents-in-suit were obvious, but reversed the District Court's finding of infringemnent. [read post]